$TRAW SEC Filings

Filed On	Filing
26 Oct 2026	FORM S-1
23 Oct 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of October 23, 2026 (this “Agreement”), by and between Roth Principal Investments, LLC, a Delaware limited liability company (the “Investor”), and Traws Pharma, Inc., a Del...
20 Oct 2026	DEFA14A
20 Oct 2026	Proxy statement: special meeting on December 3, 2026
08 Oct 2026	PRE 14A
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G
14 Aug 2026	10-Q
14 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
12 Aug 2026	SCHEDULE 13G/A
31 Jul 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
16 Jul 2026	Form 4: Pauza Charles David, Chief Science Officer Virology Granted 97,000 Stock Option (right to buy)
15 Jul 2026	Form 4: Savchuk Nikolay, Director Granted 93,000 Stock Option (right to buy)
15 Jul 2026	Form 4: Cautreels Werner, Director Granted 14,150 Stock Option (right to buy)
14 Jul 2026	Form 4: Dukes Iain D., Director Granted 274,000 Stock Option (right to buy)
14 Jul 2026	Form 4: Redfield Robert, Chief Medical Officer Granted 84,000 Stock Option (right to buy)
14 Jul 2026	Form 4: Parker Charles Nolan, Chief Financial Officer Granted 90,000 Stock Option (right to buy)
14 Jul 2026	Form 4: Shoemaker Mary Teresa, Director Granted 14,150 Stock Option (right to buy)
14 Jul 2026	Form 4: Clarke Trafford, Director Granted 14,150 Stock Option (right to buy)

Comments